OSR Holdings, Inc. 8-K

What Happened
OSR Holdings, Inc. (NASDAQ: OSRH) filed a Form 8‑K (Item 7.01) on March 16, 2026 to disclose that, during an introductory investor relations call on March 13, 2026, company management inadvertently referenced information about its drug‑development subsidiary Vaximm AG and SillaJen, Inc. (KOSDAQ: 215600) before that information had been made public. The CEO was presenting Vaximm’s business development activities when the inadvertent reference occurred; the company is furnishing the referenced information pursuant to Regulation FD.

Key Details

• Filing: Form 8‑K, Item 7.01 (Regulation FD Disclosure) filed March 16, 2026.
• Event: Introductory investor relations call held March 13, 2026 with a healthcare analyst at a New York‑based investment bank; CEO presented.
• Subjects referenced: Vaximm AG (OSR’s drug development subsidiary) and SillaJen, Inc. (KOSDAQ: 215600).
• Action taken: Company is making the inadvertently referenced information publicly available under Regulation FD.

Why It Matters
Regulation FD requires companies to publicly disclose material non‑public information so all investors have fair access. By filing this 8‑K, OSR Holdings is taking steps to correct the inadvertent pre‑release mention and ensure compliance. For investors, this filing does not report financial results or corporate actions—rather, it signals that details about Vaximm’s business development were discussed and are now being furnished publicly; investors should watch for any follow‑up disclosures that provide substantive business or financial updates.